Clayton P Smith1,2, Anna Laucis3, Stephanie Harmon1, Esther Mena1, Liza Lindenberg1, Peter L Choyke1, Baris Turkbey4. 1. Molecular Imaging Program, National Cancer Institute, NIH, Building 10 - Room B3B85, Bethesda, MD, 20892, USA. 2. Georgetown University School of Medicine, Washington, DC, USA. 3. Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA. 4. Molecular Imaging Program, National Cancer Institute, NIH, Building 10 - Room B3B85, Bethesda, MD, 20892, USA. turkbeyi@mail.nih.gov.
Abstract
PURPOSE OF REVIEW: This review aims to highlight the limitations of current standard-of-care prostate cancer (PCa) imaging and discuss novel clinical imaging in advanced disease. RECENT FINDINGS: PCa staging through imaging is important for proper selections in clinical treatment. Traditional imaging techniques for metastatic disease (i.e., computed tomography [CT], magnetic resonance imaging [MRI], and radionuclide bone scan) have suboptimal performance in early recurrent or metastatic disease. Novel positron emission tomography agents including radiolabeled prostate specific membrane antigen (PSMA), choline, and anti-18F-fluorocyclobutane-1-carboxylic acid (18F-FACBC) have demonstrated improved sensitivity and specificity in initial staging and early biochemical recurrence (BCR). Conventional imaging modalities for PCa incompletely characterize disease burden. The development of new PET tracers in combination with CT and MRI offers superior anatomic localization and biologic correlation of tumor sites, which enhance providers' abilities to make appropriate decisions regarding treatment.
PURPOSE OF REVIEW: This review aims to highlight the limitations of current standard-of-care prostate cancer (PCa) imaging and discuss novel clinical imaging in advanced disease. RECENT FINDINGS: PCa staging through imaging is important for proper selections in clinical treatment. Traditional imaging techniques for metastatic disease (i.e., computed tomography [CT], magnetic resonance imaging [MRI], and radionuclide bone scan) have suboptimal performance in early recurrent or metastatic disease. Novel positron emission tomography agents including radiolabeled prostate specific membrane antigen (PSMA), choline, and anti-18F-fluorocyclobutane-1-carboxylic acid (18F-FACBC) have demonstrated improved sensitivity and specificity in initial staging and early biochemical recurrence (BCR). Conventional imaging modalities for PCa incompletely characterize disease burden. The development of new PET tracers in combination with CT and MRI offers superior anatomic localization and biologic correlation of tumor sites, which enhance providers' abilities to make appropriate decisions regarding treatment.
Entities:
Keywords:
Choline; Fluciclovine; Novel prostate cancer imaging; PET agents; PSMA; Prostate cancer
Authors: H Schirrmeister; G Glatting; J Hetzel; K Nüssle; C Arslandemir; A K Buck; K Dziuk; A Gabelmann; S N Reske; M Hetzel Journal: J Nucl Med Date: 2001-12 Impact factor: 10.057
Authors: Charito Love; Anabella S Din; Maria B Tomas; Tomy P Kalapparambath; Christopher J Palestro Journal: Radiographics Date: 2003 Mar-Apr Impact factor: 5.333
Authors: H E Daldrup-Link; C Franzius; T M Link; D Laukamp; J Sciuk; H Jürgens; O Schober; E J Rummeny Journal: AJR Am J Roentgenol Date: 2001-07 Impact factor: 3.959
Authors: Tsuyoshi Hamaoka; John E Madewell; Donald A Podoloff; Gabriel N Hortobagyi; Naoto T Ueno Journal: J Clin Oncol Date: 2004-07-15 Impact factor: 44.544
Authors: Hedvig Hricak; Heiko Schöder; Darko Pucar; Eric Lis; Steven C Eberhardt; Chinyere N Onyebuchi; Howard I Scher Journal: Semin Oncol Date: 2003-10 Impact factor: 4.929
Authors: Mukesh G Harisinghani; Jelle Barentsz; Peter F Hahn; Willem M Deserno; Shahin Tabatabaei; Christine Hulsbergen van de Kaa; Jean de la Rosette; Ralph Weissleder Journal: N Engl J Med Date: 2003-06-19 Impact factor: 91.245
Authors: Elisa Perry; Arpit Talwar; Kim Taubman; Michael Ng; Lih-Ming Wong; Russell Booth; Tom R Sutherland Journal: Eur J Nucl Med Mol Imaging Date: 2021-01-05 Impact factor: 9.236
Authors: Venera Kuci Emruli; Leena Liljedahl; Ulrika Axelsson; Corinna Richter; Lisa Theorin; Anders Bjartell; Hans Lilja; Jenny Donovan; David Neal; Freddie C Hamdy; Carl A K Borrebaeck Journal: Proteomics Clin Appl Date: 2021-05-04 Impact factor: 3.603
Authors: Matthew P Deek; Colburn Yu; Ryan Phillips; Daniel Y Song; Curtiland Deville; Stephen Greco; Theodore L DeWeese; Emmanuel S Antonarakis; Mark Markowski; Channing Paller; Samuel Denmeade; Michael Carducci; Patrick C Walsh; Kenneth J Pienta; Mario Eisenberger; Phuoc T Tran Journal: Int J Radiat Oncol Biol Phys Date: 2019-08-13 Impact factor: 7.038
Authors: Andrew J Armstrong; Mohammed Al-Adhami; Ping Lin; Teresa Parli; Jennifer Sugg; Joyce Steinberg; Bertrand Tombal; Cora N Sternberg; Johann de Bono; Howard I Scher; Tomasz M Beer Journal: JAMA Oncol Date: 2020-02-01 Impact factor: 31.777